The National Institutes of Health (NIH) is offering a funding opportunity (RFA-AG-25-011) for early- and late-stage clinical trials focused on Alzheimer's Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD). The initiative aims to solicit applications for innovative pharmacological and non-pharmacological interventions to prevent and treat cognitive decline associated with these disorders, addressing the growing public health challenge posed by an aging population. Approximately $20 million is available for various-sized clinical trials and method-enhancing studies in fiscal year 2025, with applications opening on September 17, 2024, and closing on October 17, 2024. Interested applicants can find more information and guidelines for submission at NIH Grants and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.